RNA m⁶A modification is a driver and therapeutic target in gastric cancer.

IF 5.7 2区医学 Q2 CELL BIOLOGY

Cell Biology and Toxicology Pub Date : 2026-03-14 DOI:10.1007/s10565-026-10141-y

Qingjuan Chen, Hongzhao Lu, Dezhi Li, Tao Liu

{"title":"RNA m6A modification is a driver and therapeutic target in gastric cancer.","authors":"Qingjuan Chen, Hongzhao Lu, Dezhi Li, Tao Liu","doi":"10.1007/s10565-026-10141-y","DOIUrl":null,"url":null,"abstract":"N6-methyladenosine (m6A), the most abundant modification in eukaryotic RNAs, plays a critical role in regulating RNA stability, expression, and translation. Key m6A regulators are up- or down-regulated in human gastric cancer tissues, by Helicobacter pylori and transcription factors, and the aberrant expression is associated with poor patient prognosis. Dynamic m6A modification, orchestrated by methyltransferases, demethylases, and m6A-binding proteins, profoundly impacts gastric cancer tumorigenesis, metastasis, cancer cell stemness, immune evasion, and resistance to chemotherapy, radiotherapy, and immunotherapy. While aberrant m6A modifications and the expression levels of its regulatory factors in blood samples are novel biomarkers in gastric cancer patients, therapies targeting m6A regulators have emerged as promising approaches for treating the disease. In summary, m6A RNA methylation represents a pivotal epitranscriptomic mechanism with significant implications for gastric cancer biology and precision oncology.","PeriodicalId":9672,"journal":{"name":"Cell Biology and Toxicology","volume":" ","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2026-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102813/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Biology and Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10565-026-10141-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

N6-methyladenosine (m⁶A), the most abundant modification in eukaryotic RNAs, plays a critical role in regulating RNA stability, expression, and translation. Key m⁶A regulators are up- or down-regulated in human gastric cancer tissues, by Helicobacter pylori and transcription factors, and the aberrant expression is associated with poor patient prognosis. Dynamic m⁶A modification, orchestrated by methyltransferases, demethylases, and m⁶A-binding proteins, profoundly impacts gastric cancer tumorigenesis, metastasis, cancer cell stemness, immune evasion, and resistance to chemotherapy, radiotherapy, and immunotherapy. While aberrant m⁶A modifications and the expression levels of its regulatory factors in blood samples are novel biomarkers in gastric cancer patients, therapies targeting m⁶A regulators have emerged as promising approaches for treating the disease. In summary, m⁶A RNA methylation represents a pivotal epitranscriptomic mechanism with significant implications for gastric cancer biology and precision oncology.

查看原文本刊更多论文

RNA m6A修饰是胃癌的驱动因子和治疗靶点。

n6 -甲基腺苷（n6 - methylladenosine, m6A）是真核生物RNA中含量最多的修饰物，在调控RNA的稳定性、表达和翻译中起着至关重要的作用。关键的m6A调节因子在人胃癌组织中通过幽门螺杆菌和转录因子上调或下调，其异常表达与患者预后不良相关。在甲基转移酶、去甲基化酶和m6A结合蛋白的调控下，m6A的动态修饰深刻影响着胃癌的发生、转移、癌细胞的干细胞性、免疫逃逸以及对化疗、放疗和免疫治疗的耐药性。虽然血液样本中异常的m6A修饰及其调节因子的表达水平是胃癌患者的新生物标志物，但针对m6A调节因子的治疗已成为治疗该疾病的有希望的方法。综上所述，m6A RNA甲基化是一个关键的表转录组学机制，在胃癌生物学和精确肿瘤学中具有重要意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cell Biology and Toxicology 生物-毒理学

CiteScore

9.90

自引率

4.90%

发文量

101

审稿时长

>12 weeks

期刊介绍： Cell Biology and Toxicology (CBT) is an international journal focused on clinical and translational research with an emphasis on molecular and cell biology, genetic and epigenetic heterogeneity, drug discovery and development, and molecular pharmacology and toxicology. CBT has a disease-specific scope prioritizing publications on gene and protein-based regulation, intracellular signaling pathway dysfunction, cell type-specific function, and systems in biomedicine in drug discovery and development. CBT publishes original articles with outstanding, innovative and significant findings, important reviews on recent research advances and issues of high current interest, opinion articles of leading edge science, and rapid communication or reports, on molecular mechanisms and therapies in diseases.